Data Driven Strategies
BRINGING TOGETHER EVIDENCE AND EXCELLENCE IN ANALYTIC THINKING IN PUBLIC HEALTH
How we work
Building on existing evidence, we apply qualitative, quantitative and mixed method approaches to answer the toughest questions.
We support clients to improve
effectiveness and outcomes, maximize impact, and drive the intersection between strategy and policy.
Our network includes experts in public health impact and outcomes research, product development and introduction, performance management, evaluation and advocacy.
Based in New York, with representation in New Delhi, Carces, and Lisbon, the practice draws on experts from around the world.
What we do
business plan development
We work with clients
to develop new strategies and business plans and support them through implementation, planning and execution.
and risk assessment
We assist clients to articulate their theories of change, develop key performance indicators and “fit for purpose” risk assessment tools.
and policy analysis
We help clients evaluate
the extent to which their programs, partnerships
and policies are fit for purpose.
We synthesize the latest available data so that evidence is an integral part of strategy, policy, advocacy and programming. We commit to put this information in the public domain.
We coach senior leadership on management and execution and tailor fit for purpose technical content to get clients up to speed in emerging or complex issues.
Spark Street has contributed to the COVID response by providing pro-bono support to the City and State of New York, New York-Presbyterian Hospital, the World Bank, the Global Fund to Fight Aids, TB and Malaria, Gavi, Pfizer, the Peterson Institute, CHAP Health, UNU-IIGH, Unicef, WHO as well as government and professional colleagues from around the world to help analyze data, interpret evidence and share learning. We have also volunteered in our own local communities on issues ranging from school and arts reopening to the production of hand sanitizer. Spark Street thought pieces have been published by the Council of Foreign Relations, Foreign Policy, the Conversation, the Lancet, Atlantic Magazine and the British Medical Journal. We have been interviewed by NPR, CNN, Stat News, the Financial Times, the Economist, the New York Times, Al Jazeera, Axios news, Devex, and New York's Our Town.
Our clients are organizations working in health and global development that aspire to significantly impact the systems in which they operate.
Not for profit and intergovernmental organizations
Principal | New York, USA
Nina founded Spark Street in 2016. She has held numerous leadership positions including establishing USAID's COVID-19 Vaccine Access and Delivery Initiative and serving as its first director. She was Managing Director for Policy and Performance at Gavi, the vaccine alliance, where she led Gavi’s work in strategic planning, policy development, market-shaping, performance management, and monitoring and evaluation. Nina also served as the principal advisor and acting chief of health at Unicef, overseeing their health programs in over 150 countries.
Nina led the Policy team at Global Alliance for Tuberculosis Drug Development, where she focused on market access, product introduction and advocacy. She directed the global public health program for the Open Society Foundation and has worked for the Population Council and AVSC International (now Engender Health). She holds degrees from Harvard and Columbia Universities and teaches on the faculty at Columbia University’s Mailman School of Public Health. She is a lifetime member of the Council on Foreign Relations and currently serves as a Principal Visiting Fellow at the United Nations International Institute for Global Health. She also co-leads WHO's Research Network on COVID in educational institutions and is Commissioner for the Lancet on gender and health.
Senior Advisor | Lisbon, Portugal
Susanna is global health specialist, focusing on results-based program development, strategic planning, and analysis. She has worked with UNICEF at headquarters in New York as well as in Kyrgyzstan and Ukraine where she developed programs on maternal, child and adolescent health and wellbeing. She has a clinical background in maternal, child and school health in Finland and in India. Susanna holds an MA in Public Health and a BA in Social Sciences from Tampere University, Finland, and an MA in Russian and Eurasian Studies from European University in St. Petersburg, Russia. In addition to Finnish, is fluent in English and Russian.
Senior Advisor | Tunis, Tunisia
Abdallah is a public health specialist with extensive experience in evaluation. He started his career as a medical doctor and professor of Public Health in Tunisia. He served as the Head of Gavi's Evaluation Unit, where he introduced the concepts of theory of change and prospective evaluation to Gavi’s work. He has also worked as a consultant for WHO and served on the Global Fund’s Technical Evaluation Reference Group. Abdallah holds MSc and PhD degrees in community health from the University of Montreal and currently splits his time between Geneva and Tunis. He is fluent in English, Arabic and French.
Senior Researcher | London, England
Graphic Lead | Chennai, India
Elliot is a senior researcher, focusing on pandemic response and global governance. He has spent a decade-plus as a foreign correspondent, reporting on four continents, most recently from London. Elliot spent four years in New Delhi reporting for NPR and Time magazine. He previously worked as a producer and editor at NPR in Washington D.C. and a staff writer Slate magazine. He has a BA in Political Science from Emory University and studied International Relations and Affairs at the University of Cape Town.
Prakash started his career in finance before becoming a designer. He has worked for a Fortune 500 company as a Visualizer and enjoys exploring how to use innovative tools to visualize creative concepts.
Prakesh holds a Bachelor's of Computer Application.
The COVID-19 pandemic has highlighted the importance of vaccines as public health and pandemic preparedness tools and amplified the importance of issues ranging from equitable distribution to reliable supply of quality, affordable vaccines. These issues however are not new. Delays in time from the first dose in a high-income country to introduction at scale in a low-income country can take years. These delays are driven by several challenges, some of which are unique to the vaccine development ecosystem. The patenting and overall intellectual property (IP) protection are complex, regulatory oversight is rigorous, manufacturing processes require technical support or know-how transfer from the innovator, and market dynamics create obstacles to delivering at scale. This paper provides an overview of the vaccine research and development process and where reform of the current system could increase access.